Pfizer has just reported Q3 results, and the market's immediate reaction is quietly telling: the stock slipped 2.2% on Tuesday to $30.00, paring a week that still closes up 0.7%, while short interest has nudged back upward after several weeks of retreat. The short positioning shift is modest but worth noting. Short interest rose 5.3% across the week to 2.4% of the free float…
PFE cost to borrow surges 158% over one week to 0.375%, as short availability remains elevated at 9,999% of estimated interest.
Key data as of 12 Nov 2026
Pfizer heads into its July 28 earnings report with the Street in a quiet retreat — analysts cutting targets but holding ratings, while positioning data shows no particular stress in either direction. The most telling…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for PFE — free to start on ORTEX.
Sign up for free →Open PFE on ORTEX